Ferring Pharmaceuticals along with its affiliate Ferring Research Institute opened a 38,000 sq. ft. facility in Sorrento Valley, San Diego that will be dedicated to peptide research and therapeutics.
The company already has an R&D center in San Diego, and the new site will have expanded research laboratories for peptide medicinal chemistry, bioanalytical and DMPK (distribution, metabolism, and pharmacokinetics) activities, molecular and cell biology research, cell culture, as well as in vitro and in vivo pharmacology, explains Ferring.
The company recently gained approval for its peptide-based therapeutic for hormone-dependent prostate cancer called degarelix. It was discovered by Ferring Research Institute in San Diego and will be developed globally by Ferring Pharmaceuticals. The company is preparing to launch degarelix in the U.S. in the first quarter.
To comment on this story, go to BLOGbiotech.